Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.63 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26399000 | 0.94 | EGFR (0.64) | EGFRBRD4ALKMAP3K7JAK2 | |
| SCHEMBL26386999 | 0.93 | EGFR (0.62) | EGFRBRD4ALKMAP3K7JAK2 | |
| SCHEMBL26387336 | 0.92 | EGFR (0.61) | EGFRBRD4ALKINSRIGF1R | |
| SCHEMBL26387142 | 0.92 | EGFR (0.67) | EGFR | |
| SCHEMBL26398680 | 0.90 | EGFR (0.55) | EGFR | |
| SCHEMBL26387277 | 0.89 | EGFR (0.62) | EGFRALKINSRIGF1R | |
| SCHEMBL26379654 | 0.89 | EGFR (0.63) | EGFRBRD4ALKINSRIGF1R | |
| SCHEMBL26379421 | 0.89 | EGFR (0.63) | EGFRBRD4ALKINSRIGF1R | |
| SCHEMBL26387804 | 0.88 | EGFR (0.60) | EGFR | |
| SCHEMBL26403262 | 0.88 | EGFR (0.60) | EGFRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885BRD4 3512/4885ALK 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.